Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00453622 · ClinicalTrials.gov registry record
RISK Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Receiving CRT-D
A clinical trial of Heart Failure, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 222
- Enrollment target
- 1
- Study location
NCT00453622 is a study of Heart Failure that has completed, run by Abbott Medical Devices. The registered enrollment target is 222 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00453622, a study of Heart Failure, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 222 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to identify if the combined use of cardiac troponin enzyme (cTnT) and brain natriuretic peptide (BNP) can predict Heart Failure (HF)improvement and all-cause mortality in patients implanted with cardiac pacemaker-defibrillation devices (CRT-D). Novel biochemical markers identifying patients with high risk cardiac mortality detected by plasma protein analysis will also be evaluated. Hypothesis #1: The combined use of cTnT and BNP at just before implant will predict and risk stratify all cause mortality or HF hospitalization up to 12 months. Hypothesis #2: The change in levels of said biomarkers at different points of follow-up can predict response to CRT through 12 months. Hypothesis #3: The levels of a panel of novel inflammatory mediators, namely chemokines, will be correlated with improvement in 6-minute walk testing, quality of life, and left ventricular ejection fraction in CRT patients.
Conditions Studied
Interventions
- DEVICE Cardiac Resynchronization Therapy-Defibrillator
Study Locations (1)
Pennsylvania
- Veterans' Adminstration Pittsburgh Healthcare System - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2005-11 |
| Est. Completion | 2012-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00453622
The ClinicalTrials.gov registry entry for NCT00453622 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (89% lower). The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Cardiac Resynchronization Therapy-Defibrillator is the first listed.
NCT00453622 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00453622 about?
NCT00453622 is a clinical study titled "RISK Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Receiving CRT-D". The purpose of the study is to identify if the combined use of cardiac troponin enzyme (cTnT) and brain natriuretic peptide (BNP) can predict Heart Failure (HF)improvement and all-cause mortality in patients implanted with cardiac pacemaker-defibrillation devices (CRT-D). Novel biochemical markers i...
What is the current status of trial NCT00453622?
This trial is currently completed. The enrollment target is 222 participants. The study started on 2005-11. Estimated completion is 2012-08.
What conditions does trial NCT00453622 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT00453622?
The interventions under investigation include: Cardiac Resynchronization Therapy-Defibrillator (DEVICE).
Who is sponsoring clinical trial NCT00453622?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00453622 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.